If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Capstan Therapeutics launches with $165 million for cell engineering

University of Pennsylvania spinout uses mRNA and targeted lipid nanoparticles for cell therapy

by Gina Vitale
September 14, 2022 | A version of this story appeared in Volume 100, Issue 33


Laura Shawver
Credit: Del Mar Photographics
Laura Shawver

Capstan Therapeutics has launched with $165 million for in vivo cell engineering to treat disease. The start-up’s technology is based on research from the University of Pennsylvania, with scientific founders including Tmunity Therapeutics’s cofounder Carl June and mRNA pioneer Drew Weissman.

Capstan says its initial focus is on chimeric antigen receptor (CAR) therapies, in which certain cells, usually T cells, are modified with receptors that allow them to attack and disable harmful antigens like cancer cells. This is often done outside the body: a person’s T cells are removed, modified to express the receptors, and reintroduced into the body. Capstan instead is developing in vivo CAR therapies, in which cells are engineered while they remain in the body.

The scientific founders have demonstrated a proof-of-concept for this in vivo platform in a mouse model of cardiac fibrosis. They packaged mRNA inside a lipid nanoparticle that was decorated with an antibody. The antibody targets the nanoparticle to T cells, says scientific cofounder Jonathan Epstein, who is the chief scientific officer at Penn’s Perelman School of Medicine. The T cells took up and expressed the mRNA, which encoded for a chimeric antigen receptor that led the T cells to a target involved in the condition (Science 2022, DOI: 10.1126/science.abm0594). Capstan’s platform, which could also be used for gene editing, could be applied to cancer, monogenic blood disorders, and autoimmune diseases, says CEO Laura Shawver.

Epstein notes that the platform uses many of the tools implemented in the mRNA COVID-19 vaccines, but the team started on the project before the pandemic. “It’s fun to think that we began our work before the rest of the world knew about mRNA and lipid nanoparticles to the extent that they know about them today,” he says.

Capstan’s funding includes $102 million from a series A round populated by pharma giants including Pfizer Ventures, Leaps by Bayer, Eli Lilly and Company, and Bristol Myers Squibb.


This article was updated Sept. 20, 2022, to clarify that Capstan's platform could also be used for gene editing.



This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.